Eagle Bay Advisors LLC Sells 1,286 Shares of Pfizer Inc. (NYSE:PFE)

Eagle Bay Advisors LLC cut its stake in Pfizer Inc. (NYSE:PFE) by 16.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,603 shares of the biopharmaceutical company’s stock after selling 1,286 shares during the period. Eagle Bay Advisors LLC’s holdings in Pfizer were worth $175,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. CHICAGO TRUST Co NA lifted its holdings in shares of Pfizer by 11.8% during the 4th quarter. CHICAGO TRUST Co NA now owns 41,749 shares of the biopharmaceutical company’s stock worth $1,108,000 after acquiring an additional 4,400 shares during the period. Kieckhefer Group LLC bought a new position in shares of Pfizer during the 4th quarter worth about $93,000. Fiduciary Alliance LLC lifted its holdings in shares of Pfizer by 15.5% during the 4th quarter. Fiduciary Alliance LLC now owns 9,803 shares of the biopharmaceutical company’s stock worth $260,000 after acquiring an additional 1,319 shares during the period. Czech National Bank lifted its holdings in shares of Pfizer by 6.4% during the 4th quarter. Czech National Bank now owns 1,228,716 shares of the biopharmaceutical company’s stock worth $32,598,000 after acquiring an additional 74,350 shares during the period. Finally, West Oak Capital LLC lifted its holdings in shares of Pfizer by 1,131.0% during the 4th quarter. West Oak Capital LLC now owns 2,585 shares of the biopharmaceutical company’s stock worth $69,000 after acquiring an additional 2,375 shares during the period. 68.36% of the stock is owned by institutional investors.

Insider Transactions at Pfizer

In other news, Director Scott Gottlieb acquired 1,000 shares of Pfizer stock in a transaction that occurred on Wednesday, October 30th. The shares were acquired at an average price of $28.24 per share, with a total value of $28,240.00. Following the purchase, the director now directly owns 10,000 shares of the company’s stock, valued at $282,400. The trade was a 11.11 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.06% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

PFE has been the subject of a number of analyst reports. Guggenheim reduced their price objective on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a report on Wednesday, December 11th. Wolfe Research assumed coverage on shares of Pfizer in a report on Friday, November 15th. They set an “underperform” rating and a $25.00 price target for the company. Citigroup assumed coverage on shares of Pfizer in a report on Friday, October 25th. They set a “neutral” rating and a $30.00 price target for the company. Sanford C. Bernstein assumed coverage on shares of Pfizer in a report on Thursday, October 17th. They set a “market perform” rating and a $32.00 price target for the company. Finally, Truist Financial cut their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $32.00.

Pfizer Trading Down 0.8 %

Shares of NYSE:PFE traded down $0.22 during trading on Monday, hitting $26.50. 11,971,810 shares of the company’s stock were exchanged, compared to its average volume of 32,113,105. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54. The firm has a 50-day moving average price of $26.18 and a two-hundred day moving average price of $28.04. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The firm has a market cap of $150.18 billion, a P/E ratio of 35.81, a PEG ratio of 0.63 and a beta of 0.64.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping the consensus estimate of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The company had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. During the same quarter in the previous year, the company earned ($0.17) EPS. Pfizer’s revenue was up 31.2% on a year-over-year basis. Equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be given a dividend of $0.43 per share. This is a boost from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.49%. Pfizer’s payout ratio is currently 232.43%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.